Dongkook Pharmaceutical plans DK Centellian change for Dongkook Pharmaceutical stock

Published on 10/20/2026 at 04:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The board approved a new name on October 12, 2026 after 100 million Madeca Cream units sold. A November 27 vote follows.

Health and beauty expansion

Dongkook Pharmaceutical approved its DK Centellian name-change plan on October 12, 2026.
First-half revenue reached KRW 509.9 billion and operating profit KRW 53.4 billion.
The company held about 300 business meetings at CPHI Worldwide 2026.

Dongkook, KR7086450004, Illustration mit AI erstellt.

Dongkook Pharmaceutical (ISIN KR7086450004) is pursuing a name change to DK Centellian after its board approved the proposal on October 12, 2026, according to Seoul Economic Daily. The plan would broaden the group's identity from pharmaceuticals toward health, beauty and international distribution.

Three steps toward a broader group

The latest move follows a measurable shift in the business mix. On October 2, 2026, Seoul Economic Daily reported an IBK Investment and Securities forecast for second-half revenue of KRW 547.5 billion and operating profit of KRW 60.1 billion, increases of 16.6 percent and 22.5 percent from a year earlier.

On October 12, 2026, the proposed rebrand was tied to cumulative Madeca Cream sales above 100 million units, while Centellian24 expanded through retailers in the United States and Japan, Seoul Economic Daily reported. On October 15, 2026, Dongkook also presented its long-acting drug platform at CPHI Worldwide, where it held about 300 business consultations, according to eToday.

What does the new name mean?

The proposed identity connects the company's established drug portfolio with a faster-growing consumer-health segment. Dongkook reported first-half 2026 revenue of KRW 509.9 billion and operating profit of KRW 53.4 billion, while healthcare sales including cosmetics reached KRW 202.9 billion, up 28.7 percent year over year, Seoul Economic Daily reported. IBK expects healthcare to represent 39.3 percent of full-year revenue, compared with 31.9 percent in 2023.

Next decision arrives November 27

The proposed name change requires approval at an extraordinary shareholders meeting scheduled for November 27, 2026. The vote is the next concrete test of whether Dongkook will formally align its corporate identity with its health and beauty expansion.

Global platform adds a second growth path

Dongkook's September 22, 2026 company release said its DK-LADs platform would be presented at CPHI Worldwide alongside development work on a three-month prostate-cancer injection. The strategy therefore combines overseas pharmaceutical partnerships with the consumer reach of Centellian24.

Dongkook Pharmaceutical is listed on KOSDAQ under ticker 086450, with pharmaceuticals and medical products at the core of its business.